Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cadila Healthcare Limited
  6. Summary
    CADILAHC   INE010B01027

CADILA HEALTHCARE LIMITED

(CADILAHC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
634(c) 636.25(c) 650.65(c) 664.95(c) 655.4(c) Last
6 667 982 6 835 756 8 601 713 8 814 574 4 142 058 Volume
-0.34% +0.35% +2.26% +2.20% -1.44% Change
More quotes
Financials
Sales 2021 151 B 2 062 M 2 062 M
Net income 2021 19 068 M 261 M 261 M
Net Debt 2021 49 550 M 677 M 677 M
P/E ratio 2021 34,3x
Yield 2021 0,55%
Sales 2022 163 B 2 233 M 2 233 M
Net income 2022 26 114 M 357 M 357 M
Net Debt 2022 19 664 M 269 M 269 M
P/E ratio 2022 30,2x
Yield 2022 0,65%
Capitalization 671 B 9 169 M 9 169 M
EV / Sales 2021 4,77x
EV / Sales 2022 4,23x
Nbr of Employees 25 000
Free-Float 25,0%
More Financials
Company
Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Windlas Healthcare Pvt Ltd, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others. 
More about the company
Ratings of Cadila Healthcare Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CADILA HEALTHCARE LIMITED
02:04aCADILA HEALTHCAREá : Gets US FDA's Tentative Approval for Epilepsy Treatment Dru..
MT
06/03CADILA HEALTHCAREá : Gets US FDA's Preliminary Approval For Cancer Treatment Dru..
MT
05/30CADILA HEALTHCAREá : Gets US FDA Nod for Fluphenazine Hydrochloride
MT
05/28CADILA HEALTHCAREá : Zydus seeks DCGI approval to undertake clinical trials for ..
PU
05/28CADILA HEALTHCAREá : Zydus' new tech enabled initiative to safeguard patients ag..
PU
05/27CADILA HEALTHCAREá : Consolidated Net Profit Soars in Fiscal Q4
MT
05/27CADILA HEALTHCAREá : Zydus Cadila's EBIDTA crosses mark of Rs. 30 bn
PU
05/27CADILA HEALTHCAREá : Intimation Outcome
PU
05/27CADILA HEALTHCAREá : Seeks Regulatory Nod for Clinical Trials of COVID-19 Cockta..
MT
05/27India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktai..
RE
05/26CADILA HEALTHCAREá : Signs License Supply Agreement for Black Fungus Treatment D..
MT
05/26CADILA HEALTHCAREá : Zydus and TLC sign agreement to market Liposomal Amphoteric..
PU
05/25MARKET CHATTER : Cadila Healthcare Aims to Triple COVID-19 Vaccine Production to..
MT
05/24CADILA HEALTHCAREá : Zydus Launches Ujvira (Trastuzumab Emtansine), a Breakthrou..
PU
05/24CADILA HEALTHCAREá : Launches Biosimilar for Aggressive Breast Cancer Treatment
MT
More news
News in other languages on CADILA HEALTHCARE LIMITED
02/23Farmacéuticas indias se vuelven locales para terminar con dependencia de Chin..
2018Des laboratoires indiens intéressés par les génériques de Sanofi
More news
Chart CADILA HEALTHCARE LIMITED
Duration : Period :
Cadila Healthcare Limited Technical Analysis Chart | CADILAHC | INE010B01027 | MarketScreener
Technical analysis trends CADILA HEALTHCARE LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 597,59 INR
Last Close Price 655,40 INR
Spread / Highest target 12,9%
Spread / Average Target -8,82%
Spread / Lowest Target -46,6%
EPS Revisions
Managers and Directors
NameTitle
Sharvil Pankajbhai Patel Managing Director & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Dhaval N. Soni Secretary & Compliance Officer